Latest Breaking News On - Magda palhota - Page 1 : comparemela.com

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations

Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Erdafitinib for the Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United statesRegion flamandeKiran patelTanakam sonpavdeJanssen cilag gmbMartin vogelJanssen pharmaceuticaDrug administrationAmerican society of clinical oncologyJanssen research development in phaseAstex therapeuticsAstex pharmaceuticalsJanssen pharmaceutical companiesEuropean medicines agencyClinical developmentAstex announces new drug discovery alliance

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®. | April 21, 2023

Region flamandeUnited kingdomCity ofJanssen cilag gmbMartin vogelMagda palhotaPeter lebowitzGerhardt attardJanssen cilag gmUrology care foundationExchange commissionDrug administrationCompanies of johnsonJanssen research developmentEuropean medicines agencyUniversity college london

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

News Release Media Enquiries: Magda Palhota Phone: +351 91 2799282 Email: mpalhota@its.jnj.com . | April 21, 2023

United kingdomRegion flamandeCity ofJanssen cilag gmbPeter lebowitzMartin vogelMagda palhotaGerhardt attardEuropean commissionUniversity college londonCompanies of johnsonJanssen cilag internationalEuropean unionDrug administrationJanssen biotech incTesaro inc